This activity is supported by an independent education grant from Genmab. This online education program has been designed solely for healthcare professionals in the USA. The information in this program is not suitable for any other country.

Join leading expert Dr. Kirollos Hanna for this accredited virtual workshop. This operational workshop centers on multidisciplinary care coordination, role allocation, and workflow optimization required to build a sustainable "bispecific-ready" practice. Participants will analyze institutional readiness assessments, explore electronic medical record (EMR) clinical decision support tools (order sets and best practice advisories), establish community-to-hospital emergency escalation pathways, and define specific team responsibilities across nursing, pharmacy, emergency medicine, and oncology to support long-term delivery of bispecific antibodies in community practice.

This workshop is part of a series. Register for workshops 1, 2 and 3 below:

Workshop 1 - Selecting the Right Patient at the Right Time

Workshop 2 - From Prescription to First Dose

Workshop 3 - Managing CRS, ICANS, and Infectious Complications

Session Highlights

• Conduct practice readiness evaluations to identify infrastructure, pharmacy, nursing, and clinical workflow gaps prior to program launch.
• Define clear roles and responsibilities across the multidisciplinary care team (oncologists, APPs, infusion nurses, pharmacists, ED/inpatient clinicians).
• Integrate clinical decision support tools into electronic medical records, including standardized order sets for step-up dosing and toxicity management.
• Establish formal community-hospital communication pathways and after-hours escalation protocols for urgent patient transfers and emergency admissions.
• Identify the key functions of a "Bispecific Program Champion" in driving staff education, protocol development, and sustainable practice implementation.

Who Should Attend

This program is designed for:

• Community oncologists
• Community hematologists and hematology-oncologists
• Advanced practice providers (APPs)
• Nurse practitioners
• Oncology nurses
• Pharmacists
• Multidisciplinary care team members involved in treatment delivery and monitoring

Faculty

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, FHOPA – board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He is currently the Director of Pharmacy at Minnesota Oncology and an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine. Dr. Hanna’s research interests are focused on B-cell malignancies and genitourinary cancers. He is a recognized Fellow of the Association of Community Cancer Centers (ACCC), the Advanced Practitioner Society for Hematology/Oncology (APSHO), and the Hematology/Oncology Pharmacy Association (HOPA).

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, FHOPA, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for BeOne, BMS, and Exelixis.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 16, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-347-L01-P

Type of Activity: Application

Fee information

There is no fee for this educational activity.